



ATTORNEY DOCKET NO. VEOC.001.01US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Geuze, *et al.*

)

) Examiner: Amy DeCloux

Serial No.: 09/011,167

)

) Art Unit: 1644

Filed: 5 October, 1998

)

)

For: **CELL-DERIVED ANTIGEN PRESENTING
VESICLES**

) **STATEMENT UNDER**

) **37 CFR §1.125(b)**

)

BOX AF

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §1.125(b), Applicant states that the content of the above-referenced application originally filed in the USPTO on 2 February, 1998 and the substitute specification filed on 27 October, 2000 are the same. Rearrangements made to the originally filed text to address the objections raised by the Examiner on page 3 of paper 13 are shown in the marked-up copy of the substitute specification submitted herewith.

Respectfully submitted,

Dated: 17 April, 2001

Jennifer L. Wahlsten, Ph.D.
Reg. No. 46,226

Rae-Venter Law Group, P.C.
P.O. Box 60039
Palo Alto, CA 94306
Telephone: (650) 328-4400
Facsimile: (650) 328-4477

BRV/JLW

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231

on 4-17-01

(date)

(Signature)

(Printed Name)

Jennifer L. Wahlsten

Amendments made to the Claims
Serial No. 09/011,167

AMENDMENTS


Cancel Claim 2.

3. (Reiterated) The antigen presenting vesicle according to claim 13 further comprising at least partially processed antigens.
4. (Reiterated) The vesicle according to claim 3 wherein said at least partially processed antigens are presented in the context of MHC class I proteins.
6. (Reiterated) The antigen presenting vesicle according to claim 13, wherein said antigen presenting cell is derived from a B-lymphocyte, a Langerhans cell, a macrophage or a dendritic cell.
9. (Three Times Amended) [A method for obtaining antigen presenting vesicles] An antigen presenting vesicle having a membrane and a major histocompatibility complex (MHC) class I protein, [said method comprising] obtained by the step of:
recovering a membrane-enriched fraction obtained by differential centrifugation of membrane-containing fractions of cell culture supernatants or lysates of antigen presenting cells [whereby fractions containing said antigen presenting vesicles are obtained].
Not elected

Cancel Claim 10.

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231

on 4-17-01
(date)

(Signature)

(Printed Name)

Amendments made to the Claims
Serial No. 09/011,167

11. (Amended) [A method for obtaining antigen presenting vesicles] An antigen presenting vesicle having a membrane and a major histocompatibility complex [(MHC) protein derived from MHC] class I[I] molecule, [said method comprising] obtained by the step of:

recovering a 70,000 x g pellet obtained by differential centrifugation of membrane-containing fractions of cell culture media or lysates of antigen presenting cells containing MHC class I[I], whereby fractions containing said antigen presenting vesicles are obtained]. *Note: see below.*

12. (Amended) A [method for obtaining] purified antigen presenting vesicle[s] having a membrane and a major histocompatibility complex [(MHC) protein derived from MHC] class I[I] molecule, [said method comprising] obtained by the step of:

recovering a fraction having a buoyant density of 1.10 to 1.22 g/ml from a 70,000 x g pellet obtained by differential centrifugation of membrane-containing fractions of cell culture supernatants or lysates of antigen presenting cells containing MHC class I[I], whereby purified antigen presenting vesicles are obtained]. *Note: see above*

13. (Twice Amended) An antigen presenting vesicle free from its natural surroundings, comprising:

a membrane and a major histocompatibility complex (MHC) class I protein or a functional derivative or fragment thereof, wherein said antigen presenting vesicle is obtainable from [a] an antigen presenting cell.

Add the following new claim:

14. (New) The antigen presenting vesicle according to Claim 13, wherein said vesicle does not contain a transferrin receptor. *NEW*